Sun Pharma to Acquire Organon in Strategic Healthcare Deal

Sun Pharma, India’s largest pharmaceutical company, has entered into a definitive agreement to acquire Organon, a global healthcare firm focused on women’s health and general medicines. The transaction, announced on April 26, 2026, is set to close in early 2027, pending customary regulatory approvals and Organon stockholder consent.

Organon, spun off from Merck (known as MSD outside the US and Canada) in 2021, markets over 70 products across women’s health, biosimilars, and general medicines in 140 countries. The company reported revenues of US$6.2 billion and an adjusted EBITDA of US$1.9 billion for the fiscal year ending December 31, 2025. Organon operates six manufacturing facilities across the European Union and emerging markets, supporting its extensive global reach.

The acquisition aligns with Sun Pharma’s strategic objective to expand its innovative medicines portfolio and strengthen its position in branded generics and biosimilars. The combined entity is expected to nearly double Sun Pharma’s EBITDA and cash flow, improving its financial profile with a post-transaction net debt to EBITDA ratio of approximately 2.3x.

Sun Pharma’s Executive Chairman, Dilip Shanghvi, emphasized the complementary nature of the two companies, stating, “Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.” Kirti Ganorkar, Managing Director of Sun Pharma, highlighted the integration priorities, including business continuity and disciplined value creation, while noting significant revenue synergy opportunities through cross-selling and leveraging Organon’s talent pool.

Organon’s Executive Chair, Carrie Cox, noted that the all-cash transaction offers immediate value to stockholders and positions Organon well for future growth under Sun Pharma’s stewardship.

The deal will be executed through a merger of Organon with a Sun Pharma subsidiary, with Organon surviving the merger. The transaction remains subject to regulatory approvals across multiple jurisdictions and Organon shareholder approval.

Sun Pharma is a global leader in specialty generics with a diversified portfolio spanning innovative medicines in dermatology, ophthalmology, and oncodermatology. The company operates manufacturing facilities across five continents and serves over 100 countries. Organon’s strong presence in key markets such as the US, Europe, China, Canada, and Brazil complements Sun Pharma’s existing footprint.

Financial and legal advisory roles are divided among several firms. Sun Pharma is advised by White & Case LLP and AZB & Partners for legal matters, with financing support from Citigroup Global Markets Asia Ltd., JPMorgan Chase Bank, N.A., and MUFG Bank, Ltd. Organon’s financial advisors include Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, with legal counsel from Sullivan & Cromwell LLP and Cyril Amarchand Mangaldas.

The acquisition is expected to enhance Sun Pharma’s competitive positioning in the global pharmaceutical market, particularly in biosimilars and branded generics, sectors experiencing accelerated consolidation. The combined company aims to leverage operational synergies, including manufacturing consolidation, streamlined R&D, and expanded regulatory capabilities.

Integration challenges include aligning organizational cultures, managing global supply chains, and navigating regulatory complexities. Both companies have expressed commitment to retaining key talent and maintaining stakeholder trust throughout the process.

Upon completion, the transaction will create a stronger cash-generating entity with improved scale and diversification, supporting Sun Pharma’s long-term growth ambitions and deleveraging efforts.